Abstract
Background: Specific gene rearrangements are used for minimal residual disease (MRD) assessment, but are frequently lacking in leukaemias. In these cases, the quantification of PRAME (preferentially expressed antigen of melanoma) transcripts could be useful.
Methods: PRAME transcripts were quantified by real-time RT-PCR in normal and leukaemic samples, and the results were compared with those of conventional RT-PCR. Basal expression of PRAME was determined in 25 blood samples and 25 bone marrow samples from healthy donors, as well as in 12 haematological cell lines (Jurkat, K562, HL60, DOHH2, IM9, Daudi, CEM, KG1, DG75, 8226, U937, Raji).
Results: In paediatric acute myeloid leukaemia (AML) (n=22) and acute lymphoblastic leukaemia (ALL) (n=17), and in adult AML (n=20), abnormal PRAME expression was found in 41%, 35% and 40% of cases, respectively. To assess the sensitivity of PRAME for monitoring MRD, PRAME-positive t(8;21) AML samples with detectable AML1/ETO expression by conventional RT-PCR (n=17) were assessed for quantitative expression of AML1/ETO and PRAME. The expression of these genes was closely correlated. To confirm that PRAME expression was correlated with clinical data, the expression of PRAME was also sequentially followed in patients (n=13) from onset to cytological remission or relapse. The cytological and molecular data were highly correlated in all patients.
Conclusions: Our data confirm that PRAME quantification by real-time RT-PCR appears suitable for monitoring MRD in PRAME-positive leukaemia.
References
1. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121:823–38.10.1046/j.1365-2141.2003.04393.xSearch in Google Scholar
2. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer – Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339:591–8.Search in Google Scholar
3. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12:2006–14.10.1038/sj.leu.2401246Search in Google Scholar
4. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352:1731–8.10.1016/S0140-6736(98)04058-6Search in Google Scholar
5. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6:199–208.10.1016/S1074-7613(00)80426-4Search in Google Scholar
6. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998; 102:1376–9.10.1046/j.1365-2141.1998.00982.xSearch in Google Scholar
7. Tajeddine N, Gala JL, Louis M, Van Schoor M, Tombal B, Gailly P. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 2005; 65:7348–55.10.1158/0008-5472.CAN-04-4011Search in Google Scholar
8. McElwaine S, Mulligan C, Groet J, Spinelli M, Rinaldi A, Denyer G, et al. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol 2004; 125:729–42.10.1111/j.1365-2141.2004.04982.xSearch in Google Scholar
9. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002; 133:118–23.10.1016/S0165-4608(01)00570-2Search in Google Scholar
10. Matsushita M, Yamazaki R, Ikeda H, Kawakami Y. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies. Leuk Lymphoma 2003; 44:439–44.10.1080/1042819021000035725Search in Google Scholar PubMed
11. Matsushita M, Ikeda H, Kizaki M, Okamoto S, Ogasawara M, Ikeda Y, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 2001; 112:916–26.10.1046/j.1365-2141.2001.02670.xSearch in Google Scholar PubMed
12. Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E, et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002; 16:1176–81.10.1038/sj.leu.2402478Search in Google Scholar
13. Wattjes MP, Krauter J, Nagel S, Heidenreich O, Ganser A, Heil G. Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia. Leukemia 2000; 14:329–35.10.1038/sj.leu.2401679Search in Google Scholar
14. Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D, et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 2000; 95:2651–8.10.1182/blood.V95.8.2651Search in Google Scholar
15. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16:2115–21.10.1038/sj.leu.2402675Search in Google Scholar
16. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 2002; 116:409–20.10.1046/j.1365-2141.2002.03261.xSearch in Google Scholar
17. Elmaagacli AH, Beelen DW, Trenschel R, Schaefer UW. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 25:91–6.10.1038/sj.bmt.1702095Search in Google Scholar
18. Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002; 138:89–91.10.1016/S0165-4608(02)00582-4Search in Google Scholar
19. Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 2005; 79:257–61.10.1002/ajh.20425Search in Google Scholar PubMed
20. Deindl E, Boengler K, van Royen N, Schaper W. Differential expression of GAPDH and beta3-actin in growing collateral arteries. Mol Cell Biochem 2002; 236:139–46.10.1023/A:1016166127465Search in Google Scholar
21. Glare EM, Divjak M, Bailey MJ, Walters EH. β-Actin and GAPDH housekeeping gene expression in asthmatic airways is variable and not suitable for normalising mRNA levels. Thorax 2002; 57:765–70.10.1136/thorax.57.9.765Search in Google Scholar PubMed PubMed Central
22. Selvey S, Thompson EW, Matthaei K, Lea RA, Irving MG, Griffiths LR. β-Actin – an unsuitable internal control for RT-PCR. Mol Cell Probes 2001; 15:307–11.10.1006/mcpr.2001.0376Search in Google Scholar
23. Steele BK, Meyers C, Ozbun MA. Variable expression of some “housekeeping” genes during human keratinocyte differentiation. Anal Biochem 2002; 307:341–7.10.1016/S0003-2697(02)00045-3Search in Google Scholar
24. Gala JL, Heusterspreute M, Loric S, Hanon F, Tombal B, Van Cangh P, et al. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. Clin Chem 1998; 44:472–81.10.1093/clinchem/44.3.472Search in Google Scholar
25. Dekairelle A, Tombal B, Cosyns J, Gala J. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma (TCC) of the bladder. Clin Cancer Res 2005; 11:4724–32.10.1158/1078-0432.CCR-05-0140Search in Google Scholar
26. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U, et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000; 28:1413–22.10.1016/S0301-472X(00)00550-6Search in Google Scholar
27. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004; 108:704–11.10.1002/ijc.11623Search in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
